Vantage logo

Medtech takes on pain

Attempts to treat pain with non-opioid drugs have ended in repeated failures – but device makers have met with greater success.

Vantage logo

Cytokine players keep the faith

The demise of Nektar’s bempegaldesleukin has not stemmed the tidal wave of companies developing IL-2 and IL-15 therapies.

Vantage logo

The trigger for a Seagen buyout

Seagen is vulnerable to takeover, but whether a deal happens – and at what price – depends on at least one catalyst.

Vantage logo

The lowdown on high blood pressure

After Idorsia’s tease in resistant hypertension, data will soon emerge on other advanced assets, including long-acting RNA-based approaches.